Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.

NCT01333007 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01333007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01333007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
July 31, 2010
Completion date
May 31, 2013
Enrollment
423 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer